BlendGrowth Hormone

CJC-1295 no DAC + Ipamorelin 10mg

A dual-action secretagogue blend formulated to trigger targeted, pulsatile growth hormone release for cellular repair and metabolic studies.

CJC-1295 no DACIpamorelin

Mechanism

The blend amplifies natural pulsatile growth hormone release by concurrently stimulating the pituitary GHRH receptor with CJC-1295 no DAC and activating the ghrelin receptor pathway with Ipamorelin.

Dosing

Standard investigational regimens document a starting dose of 300 mcg total blend administered once daily on an intermittent 5-days-on, 2-days-off schedule.

Reconstitution

Reconstituting the 10 mg combined vial with 3.0 mL of bacteriostatic water yields an operational concentration of approximately 3,333 mcg/mL.

Storage

Store unmixed lyophilized vials at -20 °C, and maintain reconstituted solutions at 2–8 °C protected from light without freezing.

Mix & measure CJC-1295 no DAC + Ipamorelin 10mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure CJC-1295 no DAC + Ipamorelin 10mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration3.33mg/mL

Draw volume0.090mL

On the syringe9.00units

Total doses in vial: 33.3

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–4	300 mcg (1× daily)	~9 units (0.09 mL)
Weeks 5–8	500 mcg (1× daily)	~15 units (0.15 mL)
Weeks 9–12	600 mcg (1× daily)	~18 units (0.18 mL)
Weeks 13–16 (optional)	700 mcg (1× daily)	~21 units (0.21 mL)

Reconstitution Steps

1
Aspirate 3.0 mL of bacteriostatic water using a sterile syringe.
2
Introduce the diluent slowly against the inside glass wall of the 10 mg blend vial to prevent excess agitation.
3
Gently swirl or roll the vial until the lyophilized cake is fully dissolved without vigorous shaking.
4
Affix a label noting the reconstitution date and resulting concentration, then store immediately at 2–8 °C away from light.

Supplies Needed

Peptide Vial

Provides 10 mg of combined lyophilized CJC-1295 no DAC and Ipamorelin for reconstitution.

Insulin Syringes (U-100)

Used for precise measurement and subcutaneous administration of micro-volume doses.

Bacteriostatic Water

Serves as the sterile preservation solvent for dissolving the lyophilized peptide powder.

Alcohol Swabs

Used to sanitize the vial rubber stopper and clean the laboratory injection site.

Why researchers study it

GH & IGF-1 support

Fat metabolism & lipolysis

Recovery & tissue repair

Sleep quality

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

CJC-1295 without DAC combined with Ipamorelin represents a dual-action secretagogue formula studied for its capacity to amplify endogenous growth hormone pulses. By co-formulating a modified growth hormone-releasing hormone (GHRH) analog alongside a selective growth hormone secretagogue receptor (GHS-R) agonist, the combination engages two distinct physiological pathways simultaneously. In laboratory and experimental models, this blend is frequently assessed for its effects on tissue regeneration, lipolysis, and deep-wave sleep architecture. Because CJC-1295 no DAC features a brief half-life, it mirrors natural physiological secretion without causing excessive or continuous pituitary stimulation. Investigational protocols commonly incorporate structured cycling schedules to maintain endocrine receptor sensitivity. The shared formulation necessitates combined dosing, delivering proportional quantities of both active secretagogues in each experimental run.

References

1.Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006 — CJC-1295 (a GHRH analog) prolongs and elevates GH and IGF-1 in healthy adults
2.Raun et al., European Journal of Endocrinology, 1998 — Ipamorelin, a selective ghrelin/GHS-R agonist and GH secretagogue